2024
Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF
Kapelios C, Greene S, Mentz R, Ikeaba U, Wojdyla D, Anstrom K, Eisenstein E, Pitt B, Velazquez E, Fang J, Investigators T. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF. Circulation Heart Failure 2024, 17: e011246. PMID: 38436075, PMCID: PMC10950535, DOI: 10.1161/circheartfailure.123.011246.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionLVEF groupsKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreMildly reduced left ventricular ejection fractionBaseline left ventricular ejection fractionReduced left ventricular ejection fractionClinical summary scoreHeart failureNo significant differenceEjection fractionClinical outcomesLVEF spectrumSignificant differenceLeft ventricular ejection fraction dataEnd pointsSpectrum of ejection fractionEffect of torsemideRisk of clinical outcomesVentricular ejection fractionStudy end pointBaseline patient characteristicsClinical end pointsSummary scoreAll-cause mortalityPrevalence of comorbidities
2021
Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy
Farsky PS, White J, Al-Khalidi HR, Sueta CA, Rouleau J, Panza J, Velazquez E, O'Connor C, Investigators W, Dabrowski R, Djokovic L, Drazner M, Haddad H, Ali I, Keltai M, Naik A, Sopko G, Golba K, Andersson B, Carson P, Kukulski T. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. Journal Of Thoracic And Cardiovascular Surgery 2021, 164: 1890-1899.e4. PMID: 33610365, PMCID: PMC8260609, DOI: 10.1016/j.jtcvs.2020.12.094.Peer-Reviewed Original ResearchConceptsOptimal medical therapyCoronary artery bypassMedical therapyArtery bypassIschemic cardiomyopathyCause mortalityIschemic Heart Failure (STICH) trialVentricular ejection fraction 35Improved long-term survivalEjection fraction 35Angiotensin receptor blockersHeart Failure TrialLower cardiovascular mortalityMultivariable Cox modelOutcomes of patientsVentricular ejection fractionCoronary artery diseaseLong-term outcomesLong-term survivalSurgical revascularizationReceptor blockersCardiovascular mortalityAntiplatelet drugsArtery diseaseEjection fraction
2019
Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. Reply.
Panza JA, Velazquez EJ, Bonow RO. Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. Reply. New England Journal Of Medicine 2019, 381: 2374. PMID: 31826352, DOI: 10.1056/nejmc1913972.Peer-Reviewed Original ResearchDiastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study
Butler J, Greene SJ, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, Kalogeropoulos AP, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Scherzer R, Hsue PY, Braunwald E. Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. Journal Of Cardiac Failure 2019, 26: 371-380. PMID: 31682908, PMCID: PMC7195219, DOI: 10.1016/j.cardfail.2019.10.011.Peer-Reviewed Original ResearchConceptsDiastolic dysfunctionBody mass indexAntiretroviral therapyN-terminal pro-B-type natriuretic peptide levelsPro-B-type natriuretic peptide levelsHuman immunodeficiency virus-infected individualsCross-sectional case-control studyLow-density lipoprotein levelsHigher body mass indexHigh-sensitivity troponin IHIV RNA copiesSignificant valvular diseaseNatriuretic peptide levelsHigher interleukin-6Normal ejection fractionVirus-infected individualsLeft atrial sizePersistent atrial fibrillationProgressive cardiac remodelingSymptom frequency scoreAntiretroviral Therapy studyCardiac magnetic resonanceCase-control studyCarboxyl-terminal telopeptideCD4 countCABG Improves Outcomes in Patients With Ischemic Cardiomyopathy 10-Year Follow-Up of the STICH Trial
Howlett JG, Stebbins A, Petrie MC, Jhund PS, Castelvecchio S, Cherniavsky A, Sueta CA, Roy A, Piña IL, Wurm R, Drazner MH, Andersson B, Batlle C, Senni M, Chrzanowski L, Merkely B, Carson P, Desvigne-Nickens PM, Lee KL, Velazquez EJ, Al-Khalidi HR, Investigators S. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy 10-Year Follow-Up of the STICH Trial. JACC Heart Failure 2019, 7: 878-887. PMID: 31521682, PMCID: PMC7375257, DOI: 10.1016/j.jchf.2019.04.018.Peer-Reviewed Original ResearchConceptsRecurrent event analysisSTICH trialCause hospitalizationCause-specific hospitalizationsNon-CV eventsTotal cardiovascular hospitalizationsCoronary artery bypassVentricular ejection fractionCABG groupCause deathHF hospitalizationArtery bypassCardiovascular causesCardiovascular hospitalizationEjection fractionHeart failureIschemic cardiomyopathyRecurrent hospitalizationsMost hospitalizationsEvent analysisHospitalizationPatientsCABGRecurrent eventsTotalBurden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy
Ambrosy AP, Stevens SR, Al‐Khalidi H, Rouleau JL, Bouabdallaoui N, Carson PE, Adlbrecht C, Cleland JGF, Dabrowski R, Golba KS, Pina IL, Sueta CA, Roy A, Sopko G, Bonow RO, Velazquez EJ, Investigators O. Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. European Journal Of Heart Failure 2019, 21: 373-381. PMID: 30698316, PMCID: PMC6818499, DOI: 10.1002/ejhf.1404.Peer-Reviewed Original ResearchConceptsCharlson co-morbidity indexCCI scoreSurgical revascularizationEjection fractionMedical therapySTICH trialHeart failureIschemic cardiomyopathyKansas City Cardiomyopathy QuestionnaireCo-morbidity indexCoronary artery bypassCo-morbid conditionsHealth-related qualityCoronary artery diseaseRisk of deathProportional hazards modelYears of ageTreatment effectsGreater functional limitationsArtery bypassCause mortalityIschemic etiologyArtery diseaseWalk testBaseline confounders
2018
Revascularization for Heart Failure Can We Do Better? ∗
Ohman EM, Velazquez EJ. Revascularization for Heart Failure Can We Do Better? ∗. JACC Heart Failure 2018, 6: 527-529. PMID: 29852934, DOI: 10.1016/j.jchf.2018.05.002.Peer-Reviewed Original ResearchImpaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block
Sze E, Samad Z, Dunning A, Campbell KB, Loring Z, Atwater BD, Chiswell K, Kisslo JA, Velazquez EJ, Daubert JP. Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block. Journal Of The American College Of Cardiology 2018, 71: 306-317. PMID: 29348023, PMCID: PMC8352572, DOI: 10.1016/j.jacc.2017.11.020.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyLeft bundle branch blockCardiac resynchronization therapyWide QRS durationBundle branch blockQRS durationLVEF improvementQRS morphologyReduced LVEFBranch blockLeft ventricular ejection fraction improvementVentricular ejection fraction improvementEjection fraction improvementMean LVEF improvementNarrow QRS durationSevere valve diseaseFirst-line therapyHeart failure hospitalizationLeft ventricular functionVentricular assist deviceBaseline electrocardiographyFailure hospitalizationCombined endpointSignificant comorbiditiesResynchronization therapy
2017
Value of Cardiovascular Magnetic Resonance Imaging–Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial
Pai RG, Varadarajan P, Rouleau JL, Stebbins AL, Velazquez EJ, Al-Khalidi HR, Pohost GM. Value of Cardiovascular Magnetic Resonance Imaging–Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. JAMA Cardiology 2017, 2: 577-579. PMID: 28199489, PMCID: PMC5814980, DOI: 10.1001/jamacardio.2016.5492.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac Surgical ProceduresCardiomyopathiesFemaleHeart FailureHeart VentriclesHumansKaplan-Meier EstimateMagnetic Resonance ImagingMagnetic Resonance Imaging, CineMaleMiddle AgedMortalityMultivariate AnalysisMyocardial IschemiaOrgan SizePlastic Surgery ProceduresRisk AssessmentStroke VolumeConceptsIschemic Heart Failure (STICH) trialCardiovascular magnetic resonance imagingHeart Failure TrialVentricular ejection fractionPrecise risk stratificationMagnetic resonance imagingEjection fractionIschemic cardiomyopathySurgical treatmentFailure TrialRisk stratificationResonance imagingPatientsCardiomyopathyBaselineTrials
2015
Comparison of Transesophageal and Transthoracic Echocardiographic Measurements of Mechanism and Severity of Mitral Regurgitation in Ischemic Cardiomyopathy (from the Surgical Treatment of Ischemic Heart Failure Trial)
Grayburn PA, She L, Roberts BJ, Golba KS, Mokrzycki K, Drozdz J, Cherniavsky A, Przybylski R, Wrobel K, Asch FM, Holly TA, Haddad H, Yii M, Maurer G, Kron I, Schaff H, Velazquez EJ, Oh JK. Comparison of Transesophageal and Transthoracic Echocardiographic Measurements of Mechanism and Severity of Mitral Regurgitation in Ischemic Cardiomyopathy (from the Surgical Treatment of Ischemic Heart Failure Trial). The American Journal Of Cardiology 2015, 116: 913-918. PMID: 26170249, PMCID: PMC4554976, DOI: 10.1016/j.amjcard.2015.06.015.Peer-Reviewed Original ResearchConceptsTransesophageal echocardiographyMitral regurgitationIschemic cardiomyopathyMR gradeIschemic Heart Failure (STICH) trialMechanism of MRBaseline transesophageal echocardiographyHeart Failure TrialIndependent core laboratoryIschemic heart diseaseFunctional mitral regurgitationComparison of TransesophagealMitral annular diameterModest correlationMitral annulus diameterTransthoracic echocardiographic measurementsTransthoracic echocardiography imagingTenting areaBlood pressureSurgical treatmentFailure TrialEchocardiographic measurementsHeart diseaseTTE measurementsAnnulus diameterA balanced assessment of the STICH trial
Holly TA, Bonow RO, Velazquez EJ, Panza JA. A balanced assessment of the STICH trial. Journal Of Thoracic And Cardiovascular Surgery 2015, 149: 1683-1684. PMID: 26060013, DOI: 10.1016/j.jtcvs.2015.03.036.Peer-Reviewed Original ResearchImpact of surgical ventricular reconstruction on sphericity index in patients with ischaemic cardiomyopathy: follow‐up from the STICH trial
Choi J, Daly RC, Lin G, Lahr BD, Wiste HJ, Beaver TM, Iacovoni A, Malinowski M, Friedrich I, Rouleau JL, Favaloro RR, Sopko G, Lang IM, White HD, Milano CA, Jones RH, Lee KL, Velazquez EJ, Oh JK. Impact of surgical ventricular reconstruction on sphericity index in patients with ischaemic cardiomyopathy: follow‐up from the STICH trial. European Journal Of Heart Failure 2015, 17: 453-463. PMID: 25779355, PMCID: PMC4664050, DOI: 10.1002/ejhf.256.Peer-Reviewed Original ResearchConceptsSurgical ventricular reconstructionSVR groupSphericity indexVentricular reconstructionTreatment strategiesCoronary artery bypass graft surgeryIschemic Heart Failure (STICH) trialArtery bypass graft surgeryLV end-systolic volumeBypass graft surgeryHeart Failure TrialLV filling pressureEnd-systolic volumeIschemic cardiomyopathy patientsSmaller LV volumesLower sphericity indexImproved LVEFSTICH trialGraft surgeryWorse survivalIschemic cardiomyopathySurgical treatmentClinical outcomesFailure TrialMitral regurgitation
2014
Implication of right ventricular dysfunction on long-term outcome in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting with or without surgical ventricular reconstruction
Kukulski T, She L, Racine N, Gradinac S, Panza JA, Velazquez EJ, Chan K, Petrie MC, Lee KL, Pellikka PA, Romanov A, Biernat J, Rouleau JL, Batlle C, Rogowski J, Ferrazzi P, Zembala M, Oh JK, Investigators S. Implication of right ventricular dysfunction on long-term outcome in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting with or without surgical ventricular reconstruction. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 1312-1321. PMID: 25451487, PMCID: PMC4385741, DOI: 10.1016/j.jtcvs.2014.09.117.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiomyopathiesCoronary Artery BypassCoronary Artery DiseaseFemaleHeart VentriclesHumansKaplan-Meier EstimateMaleMiddle AgedPatient ReadmissionPlastic Surgery ProceduresProportional Hazards ModelsRisk FactorsSeverity of Illness IndexStroke VolumeTime FactorsTreatment OutcomeVentricular Dysfunction, RightVentricular Function, LeftVentricular Function, RightVentricular RemodelingConceptsRight ventricular dysfunctionCoronary artery bypassSurgical ventricular reconstructionSevere right ventricular dysfunctionArtery bypassVentricular dysfunctionRight ventricular functionVentricular reconstructionCause mortalityEnd pointVentricular functionClinical outcomesHigher pulmonary artery systolic pressureAdvanced left ventricular remodelingBaseline right ventricular functionPulmonary artery systolic pressureVentricular ejection fraction 35Ejection fraction 35Larger left ventriclePrimary end pointSecondary end pointsIschemic heart failureLow ejection fractionSevere mitral regurgitationCoronary artery diseaseExtent of Coronary and Myocardial Disease and Benefit From Surgical Revascularization in LV Dysfunction
Panza JA, Velazquez EJ, She L, Smith PK, Nicolau JC, Favaloro RR, Gradinac S, Chrzanowski L, Prabhakaran D, Howlett JG, Jasinski M, Hill JA, Szwed H, Larbalestier R, Desvigne-Nickens P, Jones RH, Lee KL, Rouleau JL. Extent of Coronary and Myocardial Disease and Benefit From Surgical Revascularization in LV Dysfunction. Journal Of The American College Of Cardiology 2014, 64: 553-561. PMID: 25104523, PMCID: PMC4129547, DOI: 10.1016/j.jacc.2014.04.064.Peer-Reviewed Original ResearchConceptsCoronary artery bypass graft surgeryOptimal medical therapyCoronary artery diseaseEnd-systolic volume indexEjection fractionSurgical revascularizationIschemic cardiomyopathyMedical therapyPrognostic factorsExtensive coronary artery diseaseArtery bypass graft surgeryIschemic left ventricular dysfunctionAdvanced ischemic cardiomyopathySubsequent survival benefitBypass graft surgeryHigh operative riskLeft ventricular dysfunctionGraft surgeryLV dysfunctionRevascularization TrialVentricular dysfunctionOperative riskSurvival benefitArtery diseaseMyocardial dysfunctionMyocardial viability and impact of surgical ventricular reconstruction on outcomes of patients with severe left ventricular dysfunction undergoing coronary artery bypass surgery: Results of the Surgical Treatment for Ischemic Heart Failure trial
Holly TA, Bonow RO, Arnold JM, Oh JK, Varadarajan P, Pohost GM, Haddad H, Jones RH, Velazquez EJ, Birkenfeld B, Asch FM, Malinowski M, Barretto R, Kalil RA, Berman DS, Sun JL, Lee KL, Panza JA. Myocardial viability and impact of surgical ventricular reconstruction on outcomes of patients with severe left ventricular dysfunction undergoing coronary artery bypass surgery: Results of the Surgical Treatment for Ischemic Heart Failure trial. Journal Of Thoracic And Cardiovascular Surgery 2014, 148: 2677-2684.e1. PMID: 25152476, PMCID: PMC4250319, DOI: 10.1016/j.jtcvs.2014.06.090.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiomyopathiesCoronary Artery BypassCoronary Artery DiseaseFemaleHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMyocardiumPlastic Surgery ProceduresPredictive Value of TestsProportional Hazards ModelsSeverity of Illness IndexTime FactorsTissue SurvivalTomography, Emission-Computed, Single-PhotonTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, LeftConceptsSurgical ventricular reconstructionCoronary artery bypass graft surgeryIschemic Heart Failure (STICH) trialArtery bypass graft surgeryCoronary artery bypass surgeryBypass graft surgeryHeart Failure TrialArtery bypass surgeryLeft ventricular dysfunctionCoronary artery diseaseType of surgeryCardiac hospitalizationVentricular reconstructionVentricular dysfunctionMyocardial viabilitySurgical treatmentGraft surgeryBypass surgeryArtery diseaseFailure TrialSevere regional left ventricular dysfunctionSevere left ventricular dysfunctionRegional left ventricular dysfunctionOutcomes of patientsIschemic heart failure
2013
Mechanisms of Functional Mitral Regurgitation in Ischemic Cardiomyopathy Determined by Transesophageal Echocardiography (from the Surgical Treatment for Ischemic Heart Failure Trial)
Golba K, Mokrzycki K, Drozdz J, Cherniavsky A, Wrobel K, Roberts BJ, Haddad H, Maurer G, Yii M, Asch FM, Handschumacher MD, Holly TA, Przybylski R, Kron I, Schaff H, Aston S, Horton J, Lee KL, Velazquez EJ, Grayburn PA, Investigators S. Mechanisms of Functional Mitral Regurgitation in Ischemic Cardiomyopathy Determined by Transesophageal Echocardiography (from the Surgical Treatment for Ischemic Heart Failure Trial). The American Journal Of Cardiology 2013, 112: 1812-1818. PMID: 24035166, PMCID: PMC3830629, DOI: 10.1016/j.amjcard.2013.07.047.Peer-Reviewed Original ResearchConceptsEnd-systolic volume indexLV end-systolic volume indexFunctional mitral regurgitationLV ejection fractionSeverity of MRMitral regurgitationVolume indexTenting areaIschemic cardiomyopathyMR gradeAnnulus areaVentricular end-systolic volume indexIschemic Heart Failure (STICH) trialSphericity indexHeart Failure TrialEffective regurgitant orifice areaPosterior leaflet angleMitral annulus areaMitral annulus diameterRegurgitant orifice areaSTICH trialSurgical treatmentEjection fractionFailure TrialTransesophageal echocardiographyHeart Failure in Sub-Saharan Africa
Bloomfield GS, Barasa FA, Doll JA, Velazquez EJ. Heart Failure in Sub-Saharan Africa. Current Cardiology Reviews 2013, 9: 157-173. PMID: 23597299, PMCID: PMC3682399, DOI: 10.2174/1573403x11309020008.Peer-Reviewed Original ResearchConceptsHeart failureDisease burdenAcute heart failureHeart failure syndromeCardiovascular disease burdenRange of etiologiesSpectrum of causesSaharan AfricaRegional disease burdenProspective registryClinical characteristicsIdiopathic causesCase seriesCase reportNational healthcare systemLifestyle habitsDiagnostic considerationsFailure syndromeSignificant burdenDisease trendsNatural historyHealthcare systemEtiologySub-Saharan AfricansBurden
2012
Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy
Oh JK, Velazquez EJ, Menicanti L, Pohost GM, Bonow RO, Lin G, Hellkamp AS, Ferrazzi P, Wos S, Rao V, Berman D, Bochenek A, Cherniavsky A, Rogowski J, Rouleau JL, Lee KL, Investigators O. Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. European Heart Journal 2012, 34: 39-47. PMID: 22584648, PMCID: PMC3533917, DOI: 10.1093/eurheartj/ehs021.Peer-Reviewed Original ResearchConceptsEnd-systolic volume indexSurgical ventricular reconstructionRegional wall motion abnormalitiesWall motion abnormalitiesEjection fractionBetter LVEFIschemic cardiomyopathyVentricular reconstructionMotion abnormalitiesLV end-systolic volume indexMedian end-systolic volume indexBaseline left ventricular functionIschemic Heart Failure (STICH) trialEnd-diastolic volume indexVolume indexBaseline LV functionCoronary artery bypassHeart Failure TrialLeft ventricular functionClinical trial registrationLeft ventricular function parametersLV global functionVentricular function parametersCardiovascular magnetic resonanceML/m2Core Lab Analysis of Baseline Echocardiographic Studies in the STICH Trial and Recommendation for Use of Echocardiography in Future Clinical Trials
Oh JK, Pellikka PA, Panza JA, Biernat J, Attisano T, Manahan BG, Wiste HJ, Lin G, Lee K, Miller FA, Stevens S, Sopko G, She L, Velazquez EJ, Investigators S. Core Lab Analysis of Baseline Echocardiographic Studies in the STICH Trial and Recommendation for Use of Echocardiography in Future Clinical Trials. Journal Of The American Society Of Echocardiography 2012, 25: 327-336. PMID: 22227341, PMCID: PMC3310914, DOI: 10.1016/j.echo.2011.12.002.Peer-Reviewed Original ResearchConceptsEjection fractionEffective regurgitant orifice areaRegurgitant orifice areaIschemic cardiomyopathyClinical practiceVentricular end-systolic volume indexPulmonary artery systolic pressureEnd-systolic volume indexLeast moderate mitral regurgitationOrifice areaBaseline echocardiographic examinationBaseline echocardiographic findingsBaseline echocardiographic studyCore lab analysisCoronary artery bypassIschemic heart failureMean ejection fractionCoronary artery diseaseModerate mitral regurgitationUse of echocardiographyMitral inflow velocityEchocardiography core laboratoryFuture clinical trialsCore laboratory analysisMitral regurgitation severity
2007
Polymorphisms in Adenosine Receptor Genes are Associated with Infarct Size in Patients with Ischemic Cardiomyopathy
Tang Z, Diamond MA, Chen J, Holly TA, Bonow RO, Dasgupta A, Hyslop T, Purzycki A, Wagner J, McNamara DM, Kukulski T, Wos S, Velazquez EJ, Ardlie K, Feldman AM. Polymorphisms in Adenosine Receptor Genes are Associated with Infarct Size in Patients with Ischemic Cardiomyopathy. Clinical Pharmacology & Therapeutics 2007, 82: 435-440. PMID: 17728764, DOI: 10.1038/sj.clpt.6100331.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsBase SequenceCardiomyopathiesCase-Control StudiesDNA Mutational AnalysisGene FrequencyGenetic Predisposition to DiseaseHeart VentriclesHumansMolecular Sequence DataMutationMyocardial InfarctionMyocardial IschemiaPhenotypePolymorphism, Single NucleotideReceptor, Adenosine A1Receptor, Adenosine A2AReceptor, Adenosine A3Risk FactorsSeverity of Illness IndexVentricular Function, LeftConceptsIschemic cardiomyopathyInfarct sizeAdenosine receptor geneReceptor geneGenetic variantsPopulation of patientsVentricular functionVentricular sizeIschemic preconditioningNormal controlsHeart responseAdenosine receptorsCardiomyopathyIschemiaPatientsIndividual responsesDNA samplesResponsePolymorphismTherapyInjuryGenesVariants